Report Overview
Report Overview
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Duchenne Muscular Dystrophy Therapeutics market size was estimated at USD 1965.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 21.10% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Duchenne Muscular Dystrophy Therapeutics market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Duchenne Muscular Dystrophy Therapeutics market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Duchenne Muscular Dystrophy Therapeutics market.
Global Duchenne Muscular Dystrophy Therapeutics Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Market Segmentation (by Type)
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Market Segmentation (by Application)
Hospitals
Clinics
Home Care
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Duchenne Muscular Dystrophy Therapeutics Market
Overview of the regional outlook of the Duchenne Muscular Dystrophy Therapeutics Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Duchenne Muscular Dystrophy Therapeutics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the markets competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porters five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Duchenne Muscular Dystrophy Therapeutics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Table of Contents
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Duchenne Muscular Dystrophy Therapeutics
- 1.2 Key Market Segments
- 1.2.1 Duchenne Muscular Dystrophy Therapeutics Segment by Type
- 1.2.2 Duchenne Muscular Dystrophy Therapeutics Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Duchenne Muscular Dystrophy Therapeutics Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) Estimates and Forecasts (2020-2035)
- 2.1.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Estimates and Forecasts (2020-2035)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 2.1 Global Market Overview
- 3 Duchenne Muscular Dystrophy Therapeutics Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Duchenne Muscular Dystrophy Therapeutics Product Life Cycle
- 3.3 Global Duchenne Muscular Dystrophy Therapeutics Sales by Manufacturers (2020-2025)
- 3.4 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Duchenne Muscular Dystrophy Therapeutics Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Duchenne Muscular Dystrophy Therapeutics Market Competitive Situation and Trends
- 3.8.1 Duchenne Muscular Dystrophy Therapeutics Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Duchenne Muscular Dystrophy Therapeutics Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Duchenne Muscular Dystrophy Therapeutics Industry Chain Analysis
- 4.1 Duchenne Muscular Dystrophy Therapeutics Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Duchenne Muscular Dystrophy Therapeutics Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Duchenne Muscular Dystrophy Therapeutics Market Porters Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Duchenne Muscular Dystrophy Therapeutics Market
- 5.7 ESG Ratings of Leading Companies
- 6 Duchenne Muscular Dystrophy Therapeutics Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2020-2025)
- 6.3 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2020-2025)
- 6.4 Global Duchenne Muscular Dystrophy Therapeutics Price by Type (2020-2025)
- 7 Duchenne Muscular Dystrophy Therapeutics Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Duchenne Muscular Dystrophy Therapeutics Market Sales by Application (2020-2025)
- 7.3 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) by Application (2020-2025)
- 7.4 Global Duchenne Muscular Dystrophy Therapeutics Sales Growth Rate by Application (2020-2025)
- 8 Duchenne Muscular Dystrophy Therapeutics Market Sales by Region
- 8.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Region
- 8.1.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Region
- 8.1.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Region
- 8.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region
- 8.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region
- 8.2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region
- 8.3 North America
- 8.3.1 North America Duchenne Muscular Dystrophy Therapeutics Sales by Country
- 8.3.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Duchenne Muscular Dystrophy Therapeutics Sales by Country
- 8.4.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Duchenne Muscular Dystrophy Therapeutics Sales by Region
- 8.5.2 Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Duchenne Muscular Dystrophy Therapeutics Sales by Country
- 8.6.2 South America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Sales by Region
- 8.7.2 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 8.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Region
- 9 Duchenne Muscular Dystrophy Therapeutics Market Production by Region
- 9.1 Global Production of Duchenne Muscular Dystrophy Therapeutics by Region(2020-2025)
- 9.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Region (2020-2025)
- 9.3 Global Duchenne Muscular Dystrophy Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Duchenne Muscular Dystrophy Therapeutics Production
- 9.4.1 North America Duchenne Muscular Dystrophy Therapeutics Production Growth Rate (2020-2025)
- 9.4.2 North America Duchenne Muscular Dystrophy Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Duchenne Muscular Dystrophy Therapeutics Production
- 9.5.1 Europe Duchenne Muscular Dystrophy Therapeutics Production Growth Rate (2020-2025)
- 9.5.2 Europe Duchenne Muscular Dystrophy Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Duchenne Muscular Dystrophy Therapeutics Production (2020-2025)
- 9.6.1 Japan Duchenne Muscular Dystrophy Therapeutics Production Growth Rate (2020-2025)
- 9.6.2 Japan Duchenne Muscular Dystrophy Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Duchenne Muscular Dystrophy Therapeutics Production (2020-2025)
- 9.7.1 China Duchenne Muscular Dystrophy Therapeutics Production Growth Rate (2020-2025)
- 9.7.2 China Duchenne Muscular Dystrophy Therapeutics Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Bristol-Myers Squibb
- 10.1.1 Bristol-Myers Squibb Basic Information
- 10.1.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.1.4 Bristol-Myers Squibb Business Overview
- 10.1.5 Bristol-Myers Squibb SWOT Analysis
- 10.1.6 Bristol-Myers Squibb Recent Developments
- 10.2 FibroGen (US)
- 10.2.1 FibroGen (US) Basic Information
- 10.2.2 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.2.4 FibroGen (US) Business Overview
- 10.2.5 FibroGen (US) SWOT Analysis
- 10.2.6 FibroGen (US) Recent Developments
- 10.3 Italfarmaco (Italy)
- 10.3.1 Italfarmaco (Italy) Basic Information
- 10.3.2 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.3.4 Italfarmaco (Italy) Business Overview
- 10.3.5 Italfarmaco (Italy) SWOT Analysis
- 10.3.6 Italfarmaco (Italy) Recent Developments
- 10.4 Marathon
- 10.4.1 Marathon Basic Information
- 10.4.2 Marathon Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.4.4 Marathon Business Overview
- 10.4.5 Marathon Recent Developments
- 10.5 NS Pharma (US)
- 10.5.1 NS Pharma (US) Basic Information
- 10.5.2 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.5.4 NS Pharma (US) Business Overview
- 10.5.5 NS Pharma (US) Recent Developments
- 10.6 PTC Therapeutics (US)
- 10.6.1 PTC Therapeutics (US) Basic Information
- 10.6.2 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.6.4 PTC Therapeutics (US) Business Overview
- 10.6.5 PTC Therapeutics (US) Recent Developments
- 10.7 Pfizer
- 10.7.1 Pfizer Basic Information
- 10.7.2 Pfizer Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.7.4 Pfizer Business Overview
- 10.7.5 Pfizer Recent Developments
- 10.8 ReveraGen BioPharma (US)
- 10.8.1 ReveraGen BioPharma (US) Basic Information
- 10.8.2 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.8.4 ReveraGen BioPharma (US) Business Overview
- 10.8.5 ReveraGen BioPharma (US) Recent Developments
- 10.9 Santhera Pharmaceuticals (Switzerland)
- 10.9.1 Santhera Pharmaceuticals (Switzerland) Basic Information
- 10.9.2 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.9.4 Santhera Pharmaceuticals (Switzerland) Business Overview
- 10.9.5 Santhera Pharmaceuticals (Switzerland) Recent Developments
- 10.10 Sarepta Therapeutics (US)
- 10.10.1 Sarepta Therapeutics (US) Basic Information
- 10.10.2 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
- 10.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
- 10.10.4 Sarepta Therapeutics (US) Business Overview
- 10.10.5 Sarepta Therapeutics (US) Recent Developments
- 10.1 Bristol-Myers Squibb
- 11 Duchenne Muscular Dystrophy Therapeutics Market Forecast by Region
- 11.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast
- 11.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country
- 11.2.3 Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Region
- 11.2.4 South America Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Duchenne Muscular Dystrophy Therapeutics by Country
- 12 Forecast Market by Type and by Application (2026-2035)
- 12.1 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Type (2026-2035)
- 12.1.1 Global Forecasted Sales of Duchenne Muscular Dystrophy Therapeutics by Type (2026-2035)
- 12.1.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Type (2026-2035)
- 12.1.3 Global Forecasted Price of Duchenne Muscular Dystrophy Therapeutics by Type (2026-2035)
- 12.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Application (2026-2035)
- 12.2.1 Global Duchenne Muscular Dystrophy Therapeutics Sales (K Units) Forecast by Application
- 12.2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) Forecast by Application (2026-2035)
- 12.1 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Type (2026-2035)
- 13 Conclusion and Key Findings